AAPL 195.95 -0.4 (-0.20%)MSFT 133.45 +0.52 (+0.39%)FB 188.78 +0.08 (+0.04%)ZNGA 5.91 -0.04 (-0.59%)NVDA 151.96 -0.17 (-0.11%)WBA 53.16 +0.06 (+0.12%)GOOG 1086.06 +0.02 (+0.00%)PIH 5.3 0 (0.00%)
AAPL 195.95 -0.4 (-0.20%)MSFT 133.45 +0.52 (+0.39%)FB 188.78 +0.08 (+0.04%)ZNGA 5.91 -0.04 (-0.59%)NVDA 151.96 -0.17 (-0.11%)WBA 53.16 +0.06 (+0.12%)GOOG 1086.06 +0.02 (+0.00%)PIH 5.3 0 (0.00%)

Discounted Cash Flow (DCF) Analysis Unlevered

CRISPR Therapeutics AG Quote

CRISPR Therapeu (CRSP)

44.07 0.25 Healthcare
All | Operating Data | Balance Sheet Data | Weighted Average Cost Of Capital | Build Up Free Cash | Terminal Value | Intrinsic Value | Results

Operating Data CRSP Quote CRISPR Ther

Balance Sheet Data CRSP Quote CRISPR Ther

Weighted Average Cost Of Capital CRSP Quote CRISPR Ther

Share Price $ 44.07
Diluted Shares Outstanding 0
Cost of Debt
Tax Rate -
After-tax Cost of Debt -
Risk Free Rate
Market Risk Premium
Cost of Equity 26.96
Total Debt 38.00
Total Equity 881.40
Total Capital 919.40
Debt Weighting 4.13
Equity Weighting 95.87
Wacc

Build Up Free Cash CRSP Quote CRISPR Ther

Terminal Value CRSP Quote CRISPR Ther

Growth in perpetuity method:
Long term growth rate
WACC (%) 26.1
Free cash flow (t+1) 0.00
Terminal Value 0.00
Present Value of Terminal Value 0.00

Intrinsic Value CRSP Quote CRISPR Ther

Enterprise Value -
Net Debt -118
Equity Value -
Shares Outstanding 20
Equity Value Per Share -

Results Unlevered DCF CRSP Quote CRISPR Ther